CUPR Key Statistics, Chart & Performance
The current stock price of CUPR is 0.4711 USD. In the past month the price decreased by -15.59%.
CUPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.21 | 16.59B | ||
| SOLV | SOLVENTUM CORP | 14.5 | 14.94B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.87 | 12.40B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.22 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.34 | 4.48B | ||
| HAE | HAEMONETICS CORP/MASS | 17.09 | 3.84B | ||
| ICUI | ICU MEDICAL INC | 19.22 | 3.78B | ||
| XRAY | DENTSPLY SIRONA INC | 8.09 | 2.55B | ||
| NEOG | NEOGEN CORP | 33.17 | 2.09B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.84 | 1.99B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.3 | 746.59M |
Related stock screener links
About CUPR
Company Profile
Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 14 full-time employees The company went IPO on 2025-04-10. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. The company has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
Company Info
CUPRINA HOLDINGS CAYMAN-A
Block 1090, Lower Delta Road, #06-08
SG
Employees: 14
Phone: 6585127275
CUPRINA HOLDINGS CAYMAN-A / CUPR FAQ
What does CUPRINA HOLDINGS CAYMAN-A do?
Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 14 full-time employees The company went IPO on 2025-04-10. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. The company has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
Can you provide the latest stock price for CUPRINA HOLDINGS CAYMAN-A?
The current stock price of CUPR is 0.4711 USD. The price increased by 0.38% in the last trading session.
What is the dividend status of CUPRINA HOLDINGS CAYMAN-A?
CUPR does not pay a dividend.
How is the ChartMill rating for CUPRINA HOLDINGS CAYMAN-A?
CUPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for CUPR stock?
CUPRINA HOLDINGS CAYMAN-A (CUPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
Would investing in CUPRINA HOLDINGS CAYMAN-A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CUPR.
CUPR Technical Analysis
CUPR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CUPR. The financial health of CUPR is average, but there are quite some concerns on its profitability.
CUPR Financial Highlights
Over the last trailing twelve months CUPR reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS decreased by -68.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.67% | ||
| ROE | -46.07% | ||
| Debt/Equity | 0.02 |